Literature DB >> 31073999

The cationic cell-penetrating KT2 peptide promotes cell membrane defects and apoptosis with autophagy inhibition in human HCT 116 colon cancer cells.

Pornsuda Maraming1, Sompong Klaynongsruang2, Patcharee Boonsiri3, Shu-Fen Peng4,5, Sakda Daduang6, Chanvit Leelayuwat7, Chamsai Pientong8, Jing-Gung Chung4, Jureerut Daduang7.   

Abstract

The anticancer activity of cationic antimicrobial peptides (AMPs) has become more interesting because some AMPs have selective recognition against cancer cells. However, their antitumor properties and underlying mechanisms in cancer cells have not been clearly understood. In this study, we evaluated the effects of KT2 (lysine/tryptophan-rich AMP) on the cellular uptake and internalization mechanism, cell viability, surface charge of the cell membrane, membrane integrity, apoptotic cell death, and autophagy in human HCT 116 colon cancer cells. We found that KT2 interacted with the cell membrane of HCT 116 cells and was internalized into HCT 116 cells via clathrin-mediated and caveolae-mediated endocytosis mechanisms. The interaction of KT2 with cells caused cell membrane structure change, elevated membrane permeability, and KT2 also affected the lipid component. The results of atomic force microscopy showed cellular membrane defects of KT2-treated cells. The internalized KT2 induced nuclear condensation and apoptotic cell death. It elevated the apoptotic factor levels including those of cytochrome c and apoptosis-inducing factor. Furthermore, KT2 inhibited autophagy by the suppression of autophagy-related 5, autophagy-related 7, autophagy-related 16 like 1, and Beclin-1 proteins. In conclusion, these results revealed the cytotoxicity of cationic KT2 against HCT 116 cells and may help to clarify the interactions between cationic AMPs and cancer cells.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  antimicrobial peptide; apoptosis; autophagy; cationic cell-penetrating KT2; membrane permeability

Mesh:

Substances:

Year:  2019        PMID: 31073999     DOI: 10.1002/jcp.28774

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

1.  Anti-metastatic Effects of Cationic KT2 Peptide (a Lysine/Tryptophan-rich Peptide) on Human Melanoma A375.S2 Cells.

Authors:  Jing-Gung Chung; Jureerut Daduang; Pornsuda Maraming; Sompong Klaynongsruang; Patcharee Boonsiri; Shu-Fen Peng; Sakda Daduang; Prapenpuksiri Rungsa; Ratree Tavichakorntrakool
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  2-Deoxy-d-glucose Promotes Buforin IIb-Induced Cytotoxicity in Prostate Cancer DU145 Cells and Xenograft Tumors.

Authors:  Yangke Wanyan; Xixi Xu; Kehang Liu; Huidan Zhang; Junai Zhen; Rong Zhang; Jumei Wen; Ping Liu; Yuqing Chen
Journal:  Molecules       Date:  2020-12-07       Impact factor: 4.411

3.  Conjugation with gold nanoparticles improves the stability of the KT2 peptide and maintains its anticancer properties.

Authors:  Pornsuda Maraming; Jureerut Daduang; James Chen Yong Kah
Journal:  RSC Adv       Date:  2021-12-20       Impact factor: 3.361

Review 4.  Targeted Antimicrobial Agents as Potential Tools for Modulating the Gut Microbiome.

Authors:  Shuli Chou; Shiqing Zhang; Huating Guo; Yung-Fu Chang; Wenjing Zhao; Xiangyu Mou
Journal:  Front Microbiol       Date:  2022-07-07       Impact factor: 6.064

5.  Scorpion Peptide Smp24 Exhibits a Potent Antitumor Effect on Human Lung Cancer Cells by Damaging the Membrane and Cytoskeleton In Vivo and In Vitro.

Authors:  Ruiyin Guo; Junfang Liu; Jinwei Chai; Yahua Gao; Mohamed A Abdel-Rahman; Xueqing Xu
Journal:  Toxins (Basel)       Date:  2022-06-28       Impact factor: 5.075

6.  Development of 68Ga-Labeled Hepatitis E Virus Nanoparticles for Targeted Drug Delivery and Diagnostics with PET.

Authors:  Elisavet Lambidis; Chun-Chieh Chen; Mo Baikoghli; Surachet Imlimthan; You Cheng Khng; Mirkka Sarparanta; R Holland Cheng; Anu J Airaksinen
Journal:  Mol Pharm       Date:  2022-07-20       Impact factor: 5.364

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.